| Nov 4 |
BioCryst Pharmaceuticals Non-GAAP EPS of -$0.07 misses by $0.01, revenue of $117.09M beats by $3.09M
|
| Nov 4 |
BioCryst Reports Third Quarter 2024 Financial Results and Provides Business Update
|
| Nov 1 |
BioCryst Pharmaceuticals Q3 2024 Earnings Preview
|
| Oct 24 |
BioCryst Presents New Real-World Evidence Showing High Adherence and Persistence Rates with ORLADEYO® (berotralstat)
|
| Oct 23 |
How Much Upside is Left in BioCryst (BCRX)? Wall Street Analysts Think 79.5%
|
| Oct 23 |
High Growth Tech Stocks To Watch In October 2024
|
| Oct 21 |
BioCryst to Report Third Quarter 2024 Financial Results on November 4
|
| Oct 14 |
BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting ORLADEYO® (berotralstat)
|
| Oct 11 |
Is BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) The Top Stock With Improving Technical Ratings According To Piper Sandler?
|
| Oct 10 |
BioCryst to Present New Real-World Evidence on Long-Term Prophylaxis in HAE, including ORLADEYO® (berotralstat), at the American College of Allergy, Asthma & Immunology 2024 Annual Scientific Meeting
|
